Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX

Autor: Manjiri M Bakre, Aditya K. Sengupta, Chandra Prakash V Serkad, Sukriti Malpani, Aparna Gunda, Ashok Bapat, Chetana Basavaraj
Rok vydání: 2020
Předmět:
Adult
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Time Factors
Concordance
Breast Neoplasms
lcsh:RC254-282
Risk Assessment
law.invention
03 medical and health sciences
0302 clinical medicine
Breast cancer
Randomized controlled trial
Predictive Value of Tests
Risk Factors
law
Internal medicine
Biomarkers
Tumor
Humans
Medicine
Radiology
Nuclear Medicine and imaging
Stage (cooking)
Human Epidermal Growth Factor Receptor 2
Aged
Neoplasm Staging
Retrospective Studies
Original Research
End point
medicine.diagnostic_test
business.industry
Gene Expression Profiling
Clinical Cancer Research
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Immunohistochemistry
030104 developmental biology
030220 oncology & carcinogenesis
Cohort
Female
Transcriptome
business
Oncotype DX
Zdroj: Cancer Medicine
Cancer Medicine, Vol 9, Iss 21, Pp 7810-7818 (2020)
ISSN: 2045-7634
Popis: Background CanAssist Breast (CAB) is a prognostic test for early stage hormone receptor‐positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) breast cancer patients, validated on Indian and Caucasian patients. The 21‐gene signature Oncotype DX (ODX) is the most widely used commercially available breast cancer prognostic test. In the current study, risk stratification of CAB is compared with that done with ODX along with the respective outcomes of these patients. Methods A cohort of 109 early stage breast cancer patients who had previously taken the ODX test were retested with CAB, and the results respectively compared with old cut‐offs of ODX as well as cut‐offs suggested by TAILORx, a prospective randomized trial of ODX. Distant metastasis‐free survival after 5 years was taken as the end point. Results CanAssist Breast stratified 83.5% of the cohort into low‐risk and 16.5% into high‐risk. With the TAILORx cut‐offs, ODX stratified the cohort into 89.9% low‐risk and 10.1% into high‐risk. The low, intermediate, and high‐risk groups with ODX old cut‐offs were 62.4%, 31.2%, and 6.4%, respectively. The overall concordance of CAB with ODX using both cut‐offs is 75%‐76%, with ~82%‐83% concordance in the low‐risk category of these tests. The NPV of the low‐risk category of CAB was 93.4%, and of ODX with TAILORx cut‐offs was 91.8% and 89.7% with old cut‐offs. Conclusions Compared to the concordance reported for other tests, CAB shows high concordance with ODX, and in addition shows comparable performance in the patient outcomes in this cohort. CAB is thus an excellent and cost‐effective alternative to ODX.
Risk stratifications and outcomes of hormone receptor‐positive/human epidermal growth factor receptor 2 negative breast cancer prognostic tests CanAssist Breast (CAB) and Oncotype DX (ODX) were compared in a cohort of 109 patients who had previously taken the ODX test. Using old cut‐offs of ODX as well as those suggested by the TAILORx study, the overall concordance of CAB with ODX was 75%‐76%, with ~82%‐83% concordance in the low‐risk category. The NPV of the low‐risk category of CAB was 93.4% and of ODX was 89.7%‐91.8%. CAB is thus an excellent and cost‐effective alternative to ODX.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje